Valproic acid reduces insulin-resistance, fat deposition and FOXO1-mediated gluconeogenesis in type-2 diabetic rat

Biochimie

Volumn 125, Issue , 2016, Pages 42-52

  Khan, Sabbir ^a   Kumar, Sandeep ^a   Jena, Gopabandhu ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Diabetes; Fat deposition; Gluconeogenesis; HDAC inhibitor; Insulin resistance; Sodium valproate

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HISTONE DEACETYLASE; INSULIN; METFORMIN; PROTEIN KINASE B BETA; STREPTOZOCIN; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL; VALPROIC ACID; FOXO1 PROTEIN, RAT; LIPID; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BIOCHEMICAL ANALYSIS; BODY WEIGHT; BROWN ADIPOSE TISSUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME INHIBITION; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; LIVER; LIVER WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; WESTERN BLOTTING; WHITE ADIPOSE TISSUE; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LIPID METABOLISM; METABOLISM;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCONEOGENESIS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VALPROIC ACID;

EID: 84960378648     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2016.02.014     Document Type: Article

References (54)

1. S.T. Keating, and A. El-Osta Epigenetic changes in diabetes Clin. Genet. 84 2013 1 10
2. G.A. Raciti, M. Longo, L. Parrillo, M. Ciccarelli, P. Mirra, P. Ungaro, P. Formisano, C. Miele, and F. Beguinot Understanding type 2 diabetes: From genetics to epigenetics Acta Diabetol. 52 2015 821 827
3. E. Nilsson, A. Matte, A. Perfilyev, V.D. de Mello, P. Kakela, J. Pihlajamaki, and C. Ling Epigenetic alterations in human liver from subjects with type 2 diabetes in parallel with reduced folate levels J. Clin. Endocrinol. Metab. 100 2015 E1491 E1501
4. T.X. Pham, and J. Lee Dietary regulation of histone acetylases and deacetylases for the prevention of metabolic diseases Nutrients 4 2012 1868 1886
5. S. Khan, and G. Jena The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: Experimental evidence for therapeutic intervention Epigenomics 7 2015 669 680
6. M.E. Walsh, A. Bhattacharya, K. Sataranatarajan, R. Qaisar, L. Sloane, M.M. Rahman, M. Kinter, and H. Van Remmen The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging Aging Cell 14 6 2015 957 970
7. J. Chen, N. Wang, M. Dong, M. Guo, Y. Zhao, Z. Zhuo, C. Zhang, X. Chi, Y. Pan, J. Jiang, H. Tang, J. Niu, D. Yang, Z. Li, X. Han, Q. Wang, and X. Chen The metabolic regulator histone deacetylase 9 contributes to glucose homeostasis abnormality induced by hepatitis C virus infection Diabetes 64 2015 4088 4098
8. M.M. Mihaylova, D.S. Vasquez, K. Ravnskjaer, P.D. Denechaud, R.T. Yu, J.G. Alvarez, M. Downes, R.M. Evans, M. Montminy, and R.J. Shaw Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis Cell 145 2011 607 621
9. L. Larsen, M. Tonnesen, S.G. Ronn, J. Storling, S. Jorgensen, P. Mascagni, C.A. Dinarello, N. Billestrup, and T. Mandrup-Poulsen Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells Diabetologia 50 2007 779 789
10. K. Sharabi, C.D. Tavares, A.K. Rines, and P. Puigserver Molecular pathophysiology of hepatic glucose production Mol. Asp. Med. 46 2015 21 33
11. C. Kaiser, and S.R. James Acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation BMC Biol. 2 2004 23
12. C. Sun, and J. Zhou Trichostatin A improves insulin stimulated glucose utilization and insulin signaling transduction through the repression of HDAC2 Biochem. Pharmacol. 76 2008 120 127
13. J.C. Weems, B.A. Griesel, and A.L. Olson Class II histone deacetylases downregulate GLUT4 transcription in response to increased cAMP signaling in cultured adipocytes and fasting mice Diabetes 61 2012 1404 1414
14. S. Raichur, S.H. Teh, K. Ohwaki, V. Gaur, Y.C. Long, M. Hargreaves, S.L. McGee, and J. Kusunoki Histone deacetylase 5 regulates glucose uptake and insulin action in muscle cells J. Mol. Endocrinol. 49 2012 203 211
15. A. Gastaldelli, S. Baldi, M. Pettiti, E. Toschi, S. Camastra, A. Natali, B.R. Landau, and E. Ferrannini Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: A quantitative study Diabetes 49 2000 1367 1373
16. I. Magnusson, D.L. Rothman, L.D. Katz, R.G. Shulman, and G.I. Shulman Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study J. Clin. Investig. 90 1992 1323 1327
17. H. Oiso, N. Furukawa, M. Suefuji, S. Shimoda, A. Ito, R. Furumai, J. Nakagawa, M. Yoshida, N. Nishino, and E. Araki The role of class I histone deacetylase (HDAC) on gluconeogenesis in liver Biochem. Biophys. Res. Commun. 404 2011 166 172
18. X. Zhou, X.Y. Zeng, H. Wang, S. Li, E. Jo, C.C. Xue, M. Tan, J.C. Molero, and J.M. Ye Hepatic FoxO1 acetylation is involved in oleanolic acid-induced memory of glycemic control: Novel findings from study 2 PLoS One 9 2014 e107231
19. S. Chateauvieux, F. Morceau, M. Dicato, and M. Diederich Molecular and therapeutic potential and toxicity of valproic acid J. Biomed. Biotechnol. 2010 2010 1 18
20. M. Gottlicher, S. Minucci, P. Zhu, O.H. Kramer, A. Schimpf, S. Giavara, J.P. Sleeman, F. Lo Coco, C. Nervi, P.G. Pelicci, and T. Heinzel Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J. 20 2001 6969 6978
21. B.M. Patel, S. Raghunathan, and U. Porwal Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus Eur. J. Pharmacol. 728 2014 128 134
22. D.K. Kochar, N. Rawat, R.P. Agrawal, A. Vyas, R. Beniwal, S.K. Kochar, and P. Garg Sodium valproate for painful diabetic neuropathy: A randomized double-blind placebo-controlled study QJM 97 2004 33 38
23. V. Rogiers, Y. Vandenberghe, and A. Vercruysse Inhibition of gluconeogenesis by sodium valproate and its metabolites in isolated rat hepatocytes Xenobiotica 15 1985 759 765
24. L.B. Avery, and N.N. Bumpus Valproic acid is a novel activator of AMP-activated protein kinase and decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice Mol. Pharmacol. 85 2014 1 10
25. S. Huang, M. Zhu, W. Wu, A. Rashid, Y. Liang, L. Hou, Q. Ning, and X. Luo Valproate pretreatment protects pancreatic beta-cells from palmitate-induced ER stress and apoptosis by inhibiting glycogen synthase kinase-3beta J. Biomed. Sci. 21 2014 38
26. A. Rakitin, S. Koks, and S. Haldre Valproate modulates glucose metabolism in patients with epilepsy after first exposure Epilepsia 56 2015 e172 175
27. J.S. Aher, S. Khan, S. Jain, K. Tikoo, and G. Jena Valproate ameliorates thioacetamide-induced fibrosis by hepatic stellate cell inactivation Hum. Exp. Toxicol. 34 2015 44 55
28. L. Breum, A. Astrup, L. Gram, T. Andersen, K.H. Stokholm, N.J. Christensen, L. Werdelin, and J. Madsen Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain Metabolism 41 1992 666 670
29. H. Kanemura, F. Sano, Y. Maeda, K. Sugita, and M. Aihara Valproate sodium enhances body weight gain in patients with childhood epilepsy: A pathogenic mechanisms and open-label clinical trial of behavior therapy Seizure 21 2012 496 500
30. S. Khan, G. Jena, and K. Tikoo Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat Exp. Mol. Pathol. 98 2015 230 239
31. S. Khan, G. Jena, K. Tikoo, and V. Kumar Valproate attenuates the proteinuria, podocyte and renal injury by facilitating autophagy and inactivation of NF-kappaB/iNOS signaling in diabetic rat Biochimie 110 2015 1 16
32. L. Zhai, S. Ye, J. Gu, D. Yang, and W. Hu Protective effects of metformin on glomerular podocytes of type 2 diabetes model rats Zhonghua Yi Xue Za Zhi 95 2015 3313 3316
33. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited FASEB J. 22 2008 659 661
34. S. Khan, and G.B. Jena Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: Study in juvenile diabetic rat Chem. Biol. Interact. 213 2014 1 12
35. S. Khan, and G.B. Jena Effect of sodium valproate on the toxicity of cyclophosphamide in the testes of mice: Influence of pre- and post-treatment schedule Toxicol. Int. 20 2013 68 76
36. S. Khan, and G. Jena Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-beta1-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats Food Chem. Toxicol. 73 2014 127 139
37. C.K. Martin, H. Han, S.D. Anton, F.L. Greenway, and S.R. Smith Effect of valproic acid on body weight, food intake, physical activity and hormones: Results of a randomized controlled trial J. Psychopharmacol. 23 2009 814 825
38. F. El-Khatib, M. Rauchenzauner, M. Lechleitner, F. Hoppichler, A. Naser, M. Waldmann, E. Trinka, I. Unterberger, G. Bauer, and G.J. Luef Valproate, weight gain and carbohydrate craving: A gender study Seizure 16 2007 226 232
39. S. Khan, T. Ahmad, C.V. Parekh, P.P. Trivedi, S. Kushwaha, and G. Jena Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice Reprod. Toxicol. 32 2011 385 394
40. A.J. Akindele, E. Otuguor, D. Singh, D. Ota, and A.S. Benebo Hypoglycemic, antilipidemic and antioxidant effects of valproic acid in alloxan-induced diabetic rats Eur. J. Pharmacol. 762 2015 174 183
41. M. Lundh, T. Galbo, S.S. Poulsen, and T. Mandrup-Poulsen Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats Diabetes Obes. Metab. 17 2015 703 707
42. J. Fang, S. Chen, N. Tong, L. Chen, D. An, J. Mu, and D. Zhou Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate Seizure 21 2012 578 582
43. G.J. Luef, M. Lechleitner, G. Bauer, E. Trinka, and P. Hengster Valproic acid modulates islet cell insulin secretion: A possible mechanism of weight gain in epilepsy patients Epilepsy Res. 55 2003 53 58
44. H. Goldberg-Stern, E. Yaacobi, M. Phillip, and L. de Vries Endocrine effects of valproic acid therapy in girls with epilepsy: A prospective study Eur. J. Paediatr. Neurol. 18 2014 759 765
45. R. Winkler, V. Benz, M. Clemenz, M. Bloch, A. Foryst-Ludwig, S. Wardat, N. Witte, M. Trappiel, P. Namsolleck, K. Mai, J. Spranger, G. Matthias, T. Roloff, O. Truee, K. Kappert, M. Schupp, P. Matthias, and U. Kintscher Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis Diabetes 61 2012 513 523
46. E. Farinelli, D. Giampaoli, A. Cenciarini, E. Cercado, and A. Verrotti Valproic acid and nonalcoholic fatty liver disease: A possible association? World J. Hepatol. 7 2015 1251 1257
47. T.K. Chang, and F.S. Abbott Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity Drug Metab. Rev. 38 2006 627 639
48. I. Mannaerts, N.R. Nuytten, V. Rogiers, K. Vanderkerken, L.A. van Grunsven, and A. Geerts Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo Hepatology 51 2010 603 614
49. D. D'Alessio The role of dysregulated glucagon secretion in type 2 diabetes Diabetes Obes. Metab. 13 Suppl. 1 2011 126 132
50. C. Haumaitre, O. Lenoir, and R. Scharfmann Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors Mol. Cell. Biol. 28 2008 6373 6383
51. M.H. Lee, M. Kim, B.H. Lee, J.H. Kim, K.S. Kang, H.L. Kim, B.I. Yoon, H. Chung, G. Kong, and M.O. Lee Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver Toxicol. Appl. Pharmacol. 226 2008 271 284
52. J. Duo, Y. Ma, G. Wang, X. Han, and C. Zhang Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line DNA Cell Biol. 32 2013 156 164
53. M. Kostrouchova, and Z. Kostrouch Valproic acid, a molecular lead to multiple regulatory pathways Folia Biol. (Praha) 53 2007 37 49
54. A. Leone, E. Di Gennaro, F. Bruzzese, A. Avallone, and A. Budillon New perspective for an old antidiabetic drug: Metformin as anticancer agent Cancer Treat. Res. 159 2014 355 376